OMER, Israel, April 21, 2020 -- Medigus Ltd. (“Medigus” or the “Company”) (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endo-surgical.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that it intends to offer and sell American Depositary Shares and pre-funded warrants in an underwritten public offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that the second installment in the amount of $1,200,000 was received in connection with the $3,000,000 agreement with Golden Grand (Shanghai Golden Grand-Medical Instruments Ltd.) for the use and sale of the company’s Medigus Ultrasonic Surgical Endostapler (MUSE™) system in China, Hong Kong, Taiwan and Macao. Golden Grand has been Medigus’ distributor of its MUSE™ systems in China since 2015. Under the terms of the agreement, in exchange for the license, training services and any goods sold, Golden Grand will pay Medigus the consideration in four installments and until the assembly of a production line in China is completed.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that following the signing of a binding letter of intent with Polyrizon Ltd., a private company engaged in developing biological gels for the purpose of protecting patients against biological threats, it has been informed by Polyrizion regarding the filing of the US patent application. The patent application, US application no. 2005/0281775, refers to formulations and methods for preventing association or interaction of viruses with a mucosal membrane and for removal of viral particles therefrom.
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a cross-distribution agreement with L1 Systems, Ltd., a wholly-owned subsidiary of Medigus, Ltd. (MDGS.TA) (MDGS.TA), for the distribution of COVID-19 related products, including ventilators. Todos is making available to L1 its comprehensive suite of testing solutions that covers best-in-class RNA extraction equipment, RNA extraction reagents, qPCR reagents, Digital PCR reagents and US-validated SARS-CoV-2 rapid point-of-care antibody test kits for non-exclusive distribution.
Intellisense Issues 60% of its Share Capital to Medigus and ScoutCam Becomes Wholly-Owned Subsidiary of Intellisense OMER, Israel, Jan. 02, 2020 -- Medigus Ltd..
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced the signing of a collaboration agreement with L-1 Systems Ltd. for the joint commercialization of various COVID-19 related products and solutions to governmental agencies and institutional healthcare organizations. Pursuant to the terms of the agreement, in consideration for jointly marketing the products with L1 Systems and providing working capital financing, Medigus shall be entitled to proceeds from sales based on a profit share model based on the scope of financing provided by Medigus, 50% of the profits in the case Medigus introduces the products, and in all other cases, of 5% of the profits.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 31.) Aptose Biosciences Inc (NASDAQ: APTO ) ...
OMER, Israel, March 06, 2020 -- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, announced today the signing of an exclusive distribution agreement with Elbit Systems Land, a subsidiary of Elbit Systems Ltd (Nasdaq and TASE: ESLT) for a period of one year. Elbit Systems manufactures LifeCan, an innovative pandemic response ventilator. As part of the agreement, Medigus will obtain exclusive rights from Elbit Systems, for marketing and sale of this product to customers in Mexico.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
OMER, Israel, May 22, 2020 -- Medigus Ltd. (Nasdaq, TASE: MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology,.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that following the signing of a collaboration agreement with L-1 Systems Ltd. for the joint commercialization of various COVID-19 related products and solutions to governmental agencies and institutional healthcare organizations, the companies received its first commercial order for COVID-19 serological test kits. The purchase order was received from a Mexican company which engages in the distribution of medical equipment to various medical centers in Mexico. Prior to placing the order, the Mexican company performed an examination of the testing kits, and following the examination, placed an order for 10,000 testing kits with a total order value of tens of thousands of dollars.
This investment represents a $10 million pre-money valuation for Scoutcam Ltd. OMER, Israel, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that Intellisense Solutions Inc. (INLL), a Nevada corporation informed Medigus that it has secured commitments for a $3.5 million investment at a pre-money valuation of $10 million for Medigus’ wholly-owned subsidiary, ScoutCam Ltd. On September 17, 2019, Medigus announced the signing of a securities exchange agreement with Intellisense which will result in Medigus’ wholly-owned subsidiary, ScoutCam Ltd., becoming a wholly-owned subsidiary of Intellisense, in exchange for 60% of the issued and outstanding share capital of Intellisense.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced the signing of a binding letter of intent with Polyrizon Ltd., private company engaged in developing biological gels for the purpose of protecting patients against biological threats. As part of the principal terms of the letter of intent, Medigus and Polyrizon will enter a commercial arrangement for the joint marketing and commercialization of Polyrizon products based on a revenue share model, focusing on a unique Biogel for the protection from COVID-19 virus. The commercial arrangement grants Medigus an exclusive right to market, resell and distribute Polyrizon’s products for a period of four years, commencing upon and subject to receipt of the requisite FDA approvals for the products.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that ScoutCam Inc. (SCTC), the Company’s subsidiary, entered into and consummated a securities purchase agreement with M. Arkin (1999) Ltd. in connection with an investment of $2,000,000. Founder and Chairman of Arkin Holdings, Moshe “Mori” Arkin, is one of Israel’s most successful life sciences and pharmaceutical entrepreneurs. A renowned industrialist and generic drug specialist, he founded Arkin Holdings, which owns a healthcare portfolio of $1 billion through four investment arms, with holdings in some 20 Israeli companies developing pharmaceutical drugs and medical equipment, such as UroGen Pharma (URGN), Keros Therapeutics (KROS) and Novolog (NVLG.TA).
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that ScoutCam Inc. (SCTC), the company’s subsidiary, presented a breakthrough with the successful integration of its wireless micro ScoutCam into medical endoscope devices, formally introducing the healthcare industry’s first operating room-ready wireless endoscope, to the company's knowledge. The device, which has been cleared for marketing by the U.S. Food and Drug Administration (FDA) and meets the Federal Communications Commission requirements, was developed for a privately held orthopedic company.
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that ScoutCam Ltd., received a purchase order for its micro cameras from a leading fortune 500 multinational healthcare corporation, in the amount of $500,000. ScoutCam Ltd. is the wholly-owned subsidiary of ScoutCam Inc. (SCTC), which is majority owned by Medigus (Medigus owns approximately 55.9% of ScoutCam Inc’s issued shares of common stock).
Medigus Ltd. (MDGS) (MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced the signing of a $4,000,000 non-binding MOU agreement with L-1 Systems Ltd. for the licensing and sale of know-how and goods relating to the Medigus Ultrasonic Surgical Endostapler (MUSE™) system in the Latin America region. In addition, Medigus shall receive an additional payment of US$500,000 in consideration for support services to be provided during the first year following the execution of the definitive agreement. Under the terms of the MOU, the parties will use commercially reasonable efforts to negotiate and execute the definitive agreement within one hundred and eighty (180) days of the date hereof.
Medigus Ltd. (Nasdaq, TASE: MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced the pricing of an underwritten public offering of 3,333,334 American Depositary Shares (the “ADSs”) (or pre-funded ADS purchase warrants, each to purchase one ADS (the “Pre-Funded Warrants”) in lieu thereof). Medigus Ltd. intends to use the proceeds of the offering for working capital and general corporate purposes. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the sole book-running manager for the offering.